RxDoctor Payments Data

Robin Hammack

Adult Health · Sarasota, FLNPI 1881036218

Payments from drug & device makers

$10,867in general payments, 2019–2025

Across 544 payments — averaging $19.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$790
  • Gilead$714
  • AstraZeneca$671
  • E.r. Squibb & Sons, L.L.C.$664
  • Merck$569
  • Daiichi Sankyo Inc.$550
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$10,63198%
  • Education$2362%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis47$790
Gilead(2 entities)33$714
AstraZeneca(2 entities)35$671
E.r. Squibb & Sons, L.L.C.38$664
Merck26$569
Daiichi Sankyo Inc.21$550
Incyte Corporation22$509
Bristol Myers Squibb19$444
Johnson & Johnson22$435
Seagen Inc.26$428
Pfizer20$406
Astellas Pharma US Inc17$301
GSK12$296
Lilly USA, LLC11$254
Bayer13$234
Eisai Inc.11$228
AbbVie10$223
Takeda Pharmaceuticals U.S.A., Inc.7$214
Array Biopharma Inc11$200
Sobi, Inc11$195
Jazz Pharmaceuticals Inc.7$165
Amgen11$161
Beigene USA, Inc.7$148
Sanofi6$114
Deciphera Pharmaceuticals Inc.5$105
Beone Medicines USA, Inc.4$97
Genentech USA, Inc.6$96
Acrotech Biopharma Inc.5$94
Mirati Therapeutics, Inc.5$86
Pharmacosmos Therapeutics Inc.5$82
Pharmaessentia USA Corporation3$70
Exelixis Inc.3$69
Tersera Therapeutics LLC3$63
Rigel Pharmaceuticals, Inc.2$63
Boehringer Ingelheim2$62
Puma Biotechnology, Inc.4$62
Epizyme, Inc.4$59
Regeneron Healthcare Solutions, Inc.2$59
Pharmacyclics LLC, An Abbvie Company3$59
Servier Pharmaceuticals LLC3$58
Genmab U.S., Inc.3$57
Stemline Therapeutics Inc.2$56
CTI Biopharma Corp.3$51
Dendreon Pharmaceuticals LLC2$50
G1 Therapeutics, Inc.3$46
Recordati_rare_diseases_inc.2$41
ADC Therapeutics America, Inc.2$36
Heron Therapeutics, Inc.2$34
Sumitomo Pharma America, Inc.2$31
Legend Biotech USA Inc.1$28
Taiho Oncology, Inc.2$28
Blueprint Medicines Corporation2$28
Dova Pharmaceuticals2$28
Argenx US, Inc.1$26
Telix Pharmaceuticals1$25
Alnylam Pharmaceuticals Inc.1$23
GE HealthCare1$22
Morphosys, US Inc.1$20
AMAG Pharmaceuticals, Inc.1$18
EMD Serono, Inc.1$18

How this compares

$10,867 in reported general payments places this provider in the 95th percentile of 2,237 adult health providers in Florida.

See all adult health providers in Florida

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban22$21,496
Ondansetron OdtOndansetron30$776
Hydroxyurea12$380
Anastrozole44$372
Prednisone19$74

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$406$21,49622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,237 adult health providers in Florida.

Other adult health in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →